Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTHFree Report) in a research report report published on Friday. The firm issued a sell rating on the stock.

Bio-Path Stock Performance

Bio-Path stock opened at $4.60 on Friday. Bio-Path has a 52 week low of $4.60 and a 52 week high of $44.80. The firm has a market cap of $3.12 million, a P/E ratio of -0.11 and a beta of 0.66. The business’s fifty day moving average is $8.13 and its two-hundred day moving average is $9.18.

Bio-Path (NASDAQ:BPTHGet Free Report) last posted its quarterly earnings data on Friday, March 8th. The company reported ($5.40) earnings per share for the quarter, meeting the consensus estimate of ($5.40). During the same quarter last year, the firm posted ($10.60) earnings per share. On average, equities research analysts predict that Bio-Path will post -20.8 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of Bio-Path by 77.5% in the 4th quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock worth $125,000 after purchasing an additional 117,914 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of Bio-Path in the 3rd quarter valued at about $77,000. Renaissance Technologies LLC acquired a new stake in shares of Bio-Path in the 2nd quarter valued at approximately $70,000. Citadel Advisors LLC bought a new position in Bio-Path during the 3rd quarter worth approximately $35,000. Finally, Virtu Financial LLC acquired a new position in Bio-Path during the first quarter valued at approximately $38,000. 5.74% of the stock is currently owned by institutional investors and hedge funds.

About Bio-Path

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Further Reading

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.